Blog Exposure – Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma

Stock Monitor: Myovant Sciences Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want access to our free research report on Biohaven Pharma Holding Co. Ltd (NYSE: BHVN) (“Biohaven”), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BHVN as the Company’s latest news hit the wire. On June 19, 2018, the Company announced that it has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000), or BHV-3500, and certain derivative compounds thereof to Royalty Pharma for $100 million. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Myovant Sciences Ltd (NYSE: MYOV), which also belongs to the Healthcare sector as the Company Biohaven Pharma Holding. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=MYOV

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Biohaven Pharma Holding most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BHVN

Funding will Provide Biohaven the Resources to Support Biohaven’s Rimegepant Development Program through NDA Filing

Royalty Pharma will also purchase $50 million in common shares of Biohaven at a price of $45.00 per share, representing an approximately 19% premium over the 15-day volume-weighted average price. The participation rate commences at 2.10% on global annual net sales of products up to and equal to $1.5 billion, declining to 1.50% on global annual net sales of products exceeding $1.5 billion. These transactions are expected to provide sufficient cash to fund operations through the end of 2019.

This total of $150 million funding will provide Biohaven the resources to support the rimegepant development program through an NDA filing; the progression of BHV-3500 into a Phase-2 study; the advancement of the glutamate modulator platform; and a further development of the Company’s earlier pipeline and clinical infrastructure.

Transaction Demonstrates Value of Biohaven’s Late-Stage CGRP-Receptor Antagonist Products in Migraine

Commenting on the announcement, Vlad Coric, M.D., Chief Executive Officer (CEO) of Biohaven, stated that this transaction will allow the Company to fully fund its current pipeline portfolio through the end of 2019, and demonstrates the value of Biohaven’s late-stage calcitonin gene-related peptide (CGRP)-receptor antagonist products in migraine. Coric added that the Company is excited that Royalty Pharma will be joining as investors in Biohaven and looks forward to their participation as it continues to advance its product development candidates into the clinic with the goal of bringing new novel treatments to patients in areas of high unmet need.

News report suggests that post announcement of the news, shares of Biohaven surged in pre-market trade.

Biohaven Inked Restructuring License Deal with Bristol-Myers Squibb to Reduce Royalties Payable on its Migraine Product Candidates

On March 12, 2018, the Company announced a restructuring of its global license agreement with Bristol-Myers Squibb Co. for Biohaven’s small molecule CGRP receptor antagonist platform, which includes its product candidates, rimegepant, for the acute treatment of migraine; as well as BHV-3500, for the acute treatment and prevention of migraine. As part of the restructuring, Biohaven would make an upfront payment of $50 million to Bristol-Myers Squibb in return for a low-single digit reduction in the royalties payable on the net sales of rimegepant, and a mid-single digit reduction in the royalties payable on the net sales of BHV-3500.

About Royalty Pharma

Established in 1996, Royalty Pharma is the industry leader in investing in marketed and late stage biopharmaceutical products. Central to Royalty Pharma’s investment strategy is acquiring economic interests in leading pharmaceutical and biotechnology products, and holding these interests for the long-term as part of a diversified portfolio.

About Biohaven Pharmaceutical Holding Co. Ltd

Founded in 2013 and headquartered in New Haven, Connecticut, Biohaven is a clinical-stage biopharmaceutical organization with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.

Stock Performance Snapshot

June 20, 2018 – At Wednesday’s closing bell, Biohaven Pharma’s stock declined 2.25%, ending the trading session at $41.34.

Volume traded for the day: 525.32 thousand shares.

Stock performance in the last month – up 27.40%; previous three-month period – up 44.55%; past twelve-month period – up 61.61%; and year-to-date – up 53.22%

After yesterday’s close, Biohaven Pharma’s market cap was at $1.62 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.5% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 503283